These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 7682523)

  • 41. First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity.
    Dyke CK; Steinhubl SR; Kleiman NS; Cannon RO; Aberle LG; Lin M; Myles SK; Melloni C; Harrington RA; Alexander JH; Becker RC; Rusconi CP
    Circulation; 2006 Dec; 114(23):2490-7. PubMed ID: 17101847
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recommendations of the Oligonucleotide Safety Working Group's Formulated Oligonucleotide Subcommittee for the Safety Assessment of Formulated Oligonucleotide-Based Therapeutics.
    Marlowe JL; Akopian V; Karmali P; Kornbrust D; Lockridge J; Semple S
    Nucleic Acid Ther; 2017 Aug; 27(4):183-196. PubMed ID: 28609186
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nucleic acid therapeutic carriers with on-demand triggered release.
    Venkatesh S; Wower J; Byrne ME
    Bioconjug Chem; 2009 Sep; 20(9):1773-82. PubMed ID: 19670897
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Binding of short oligonucleotides to RNA: studies of the binding of common RNA structural motifs to isoenergetic microarrays.
    Kierzek E
    Biochemistry; 2009 Dec; 48(48):11344-56. PubMed ID: 19835418
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Building oligonucleotide therapeutics using non-natural chemistries.
    Wilson C; Keefe AD
    Curr Opin Chem Biol; 2006 Dec; 10(6):607-14. PubMed ID: 17049298
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Progress in antisense oligonucleotide therapeutics.
    Crooke ST; Bennett CF
    Annu Rev Pharmacol Toxicol; 1996; 36():107-29. PubMed ID: 8725384
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antisense oligonucleotides as therapeutics for malignant diseases.
    Ho PT; Parkinson DR
    Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A brief history, status, and perspective of modified oligonucleotides for chemotherapeutic applications.
    Cook PD
    Curr Protoc Nucleic Acid Chem; 2001 May; Chapter 4():Unit 4.1. PubMed ID: 18428848
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Oligonucleotides as therapeutic tools for brain disorders: Focus on major depressive disorder and Parkinson's disease.
    Bortolozzi A; Manashirov S; Chen A; Artigas F
    Pharmacol Ther; 2021 Nov; 227():107873. PubMed ID: 33915178
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recent advances in the medicinal chemistry of antisense oligonucleotides.
    Uhlmann E
    Curr Opin Drug Discov Devel; 2000 Mar; 3(2):203-13. PubMed ID: 19649851
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Strategies for designing clinical trials for oligonucleotide therapeutics.
    Wacheck V
    Drug Discov Today; 2004 Nov; 9(21):918-23. PubMed ID: 15501726
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Synthesis of terminally modified oligonucleotides and their hybridization dependence on the size of the target RNAs.
    Seio K; Takaku Y; Miyazaki K; Kurohagi S; Masaki Y; Ohkubo A; Sekine M
    Org Biomol Chem; 2009 Jun; 7(11):2440-51. PubMed ID: 19462056
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Recent progress and prospect in oligonucleotide therapeutics].
    Yoshioka K; Kuwahara H; Nishina K; Nagata T; Yokota T
    Nihon Rinsho; 2015 Jun; 73(6):1057-65. PubMed ID: 26065142
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Medicinal chemistry of antisense oligonucleotides--future opportunities.
    Cook PD
    Anticancer Drug Des; 1991 Dec; 6(6):585-607. PubMed ID: 1772571
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rational and combinatorial strategies for designing oligonucleotides targeted to RNA structures.
    Toulmé JJ; Le Tinévez R; Boiziau C; Dausse E
    Nucleic Acids Symp Ser; 1997; (36):39-41. PubMed ID: 9478200
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Oligonucleotide analogues: an overview.
    Matteucci M
    Ciba Found Symp; 1997; 209():5-14; discussion 14-8. PubMed ID: 9383565
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Oligonucleotide therapeutics.
    Cohen JS
    Trends Biotechnol; 1992 Mar; 10(3):87-91. PubMed ID: 1371926
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oligonucleotides and derivatives as gene-specific control agents.
    Sun JS; Hélène C
    Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):489-505. PubMed ID: 14565225
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antisense Oligonucleotides Internally Labeled with Peptides Show Improved Target Recognition and Stability to Enzymatic Degradation.
    Taskova M; Madsen CS; Jensen KJ; Hansen LH; Vester B; Astakhova K
    Bioconjug Chem; 2017 Mar; 28(3):768-774. PubMed ID: 28292178
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Advances in quantitative bioanalysis of oligonucleotide biomarkers and therapeutics.
    Wang L; Ji C
    Bioanalysis; 2016; 8(2):143-55. PubMed ID: 26652713
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.